Downstream glucose lowering

Sodium-glucose cotransporter 2 inhibitors are being pursued by a number of pharmaceutical companies as a novel class of diabetes drugs, with three companies reporting compounds in Phase II testing. AstraZeneca plc last week joined in the race by entering into a deal to co-develop one of the advanced candidates:

Read the full 495 word article

How to gain access

Continue reading with a
two-week free trial.